Birkett Kevin Geoffrey 4
4 · Ensysce Biosciences, Inc. · Filed Feb 24, 2022
Insider Transaction Report
Form 4
Birkett Kevin Geoffrey
Chief Commercial Officer
Transactions
- Award
Stock Option
2022-02-17+50,000→ 50,000 totalExercise: $1.40Exp: 2032-02-17→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.